Rare *CRHR2* and *GRM8* variants identified as candidate factors associated with eating
 disorders in Japanese patients.
 3

4 Akira Oka^{1, 2*}, Shinji Hadano^{1, 2, 4}, Mahoko Takahashi Ueda³, So Nakagawa^{1, 2, 4}, Gen Komaki⁵,

5 Tetsuya Ando^{6,7}

6

¹Department of Molecular Life Sciences, Division of Basic Medical Science and Molecular
Medicine, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa 259-1193,
Japan

¹⁰ ²The Institute of Medical Sciences, Tokai University, 143 Shimokasuya, Isehara, Kanagawa,

- 11 259-1193, Japan
- ¹² ³Department of Genomic Function and Diversity, Medical Research Institute, Tokyo Medical and
- 13 Dental University, Bunkyo, Tokyo, 113-8510 Japan
- ⁴Micro/Nano Technology Center, Tokai University, Hiratsuka, Kanagawa, Japan
- ⁵ Faculty of Medical Science, Fukuoka International University of Health and Welfare,
- 16 Momochihama, Sawara-ku, Fukuoka 814-0001, Japan
- ⁶Department of Psychosomatic Medicine, Faculty of Medicine, School of Medicine, International
- 18 University of Health and Welfare, 4-3 Kozunomori, Narita, Chiba 286-8686, Japan
- ¹⁹ ⁷Department of Behavioral Medicine, National Institute of Mental Health, National Center of
- 20 Neurology and Psychiatry, 4-1-1 Ogawa-higashi, Kodaira, Tokyo 187-8553, Japan
- 21 * Corresponding author
- 22 Email: <u>oka246@is.icc.u-tokai.ac.jp</u>
- 23
- 24 Keywords. Eating disorder, CRHR2, GRM8, whole exome sequencing, affected sib-pair

25

1 Abstract

2 Eating disorders (EDs) are a type of psychiatric disorder characterized by pathological eating and 3 related behavior and considered to be highly heritable. The purpose of this study was to explore rare 4 variants expected to display biological functions associated with the etiology of EDs. We performed 5 whole exome sequencing (WES) of affected sib-pairs corresponding to disease subtype through their 6 lifetime and their parents. From those results, rare single nucleotide variants (SNVs) concordant with 7 sib-pairs were extracted and estimated to be most deleterious in the examined families. Two 8 non-synonymous SNVs located on corticotropin releasing hormone receptor 2 (CRHR2) and 9 glutamate metabotropic receptor 8 (GRM8) were identified as candidate disease susceptibility factors. 10 The SNV of *CRHR2* was included within the cholesterol binding motif of the transmembrane helices 11 region, while the SNV of *GRM8* was found to contribute to hydrogen bonds for an α -helix structure. 12CRHR2 plays important roles in the serotoninergic system of dorsal raphe nuclei, which is involved 13 with feeding and stress-coping behavior. Moreover, GRM8 modulates glutamatergic 14neurotransmission, and is also considered to have effects on dopaminergic and adrenergic 15neurotransmission. Further investigation regarding the biological function of these variants may 16 provide an opportunity for elucidate the pathogenesis of EDs.

17

18

1 1. Introduction

2 Eating behavior can be severely affected by eating disorders (EDs), including anorexia nervosa (AN) 3 and bulimia nervosa (BN). The main manifestations of AN are dietary restriction, fasting, excessive 4 exercise, or other weight control or loss behaviors as resistance to maintenance of normal body 5 weight. On the other hand, BN is characterized by repeated binge eating and inadequate 6 compensatory behaviors to avoid weight gain. Manifestations shared by these disorders include 7 aspiration for weight loss, fear of weight gain, and self-evaluation unduly influenced by body shape 8 and weight. Moreover, twin and familial studies demonstrated that genetic predisposition to AN and 9 BN is shared, at least in part [1-3]. The Diagnostic and Statistical Manual of Mental Disorders 10 (DSM-5) provides diagnostic criteria for a subgroup of AN defined as restricting type (AN-R), 11 which include severe dietary restriction without regular binge eating and/or purging behaviors, as 12well as binge-eating/purging type (AN-BP) with regular binge eating and/or purging behaviors.

13 A recent GWAS for AN in European identified eight significant common variants [4]. 14 However, that study captured only 1.7% of the phenotypic variance, thus additional subjects would 15be required for future replication studies [4]. On the other hand, a sequencing study with linkage 16 analysis was performed using two large families with AN and BN, and those findings suggested that 17 each rare missense variant in estrogen-related receptor α (ESRRA) and histone deacetylase 4 18 (HDAC4) is associated with EDs [3]. ESRRA null mice also display behavioral deficits relevant to EDs such as AN [5]. Moreover, $HDAC4^{A778T}$ mice carrying the missense variant demonstrate several 19 20 ED-related feeding and behavioral deficits in a gender-dependent manner [6, 7].

Swedish twin study for EDs demonstrated that concordance rates in monozygotic twins were higher than dizygotic twins within the same disease subtype, on the other hand, the rates were similar in the different subtype [1]. Therefore, in the current study, to use subjects expected to be higher heritability we selected seven affected sib-pairs corresponding to disease subtype through their lifetime for whole exome sequencing (WES) for exploring rare variants functionally related to the pathogenesis of EDs. However, the statistical power was quite insufficient to perform genetic association and linkage analysis. Therefore, we explored the most deleterious coding variants shared

1 with sib-pairs in each family.

2

3 **2. Materials and methods**

4 2.1 Patients and families

5 Upon approval of the experimental procedures from the relevant ethical committees at the National 6 Institute of Mental Health, National Center of Neurology and Psychiatry (number: A2013-054) and 7 Tokai University (number: 14I-60), we obtained written informed consent in accordance with the 8 Declaration of Helsinki from 30 sib pairs and their family members prior to collection of DNA 9 samples. Among all subjects we selected 7 sib pairs corresponding to disease subtype through their 10 lifetime for reduction of sample heterogeneity and elevation of likelihood of identification of 11 susceptibility variants [8], though family P8 included a brother who displayed a different subtype 12(Fig. 1 and Supplementary Table 1). The IDs of the samples in this paper were reassigned for the 13 experiment, therefore these IDs could not identify individuals. They are 15 individuals affected with 14 EDs and 11 unaffected individuals, all of Japanese origin. They are also three ANR and three BN 15families, and one family displayed a diagnostic crossover from ANR to BN. Of the cases, each was 16 diagnosed according to the DSM-IV criteria in Japan. DSV-IV eating disorder diagnosis was made 17 by expert of psychosomatic doctors or psychiatrists expertized on eating disorders. DNA was 18 extracted using a QIAamp DNA blood kit (QIAGEN, Hilden, Germany).

19

20 2.2 Genomic library construction and sequencing

For exon fragment capture and sequencing, an Agilent SureSelect Target Enrichment, v. 5 (50 Mbp),
was used. Sequence analysis was performed using an Illumina Genome Analyzer IIx, HiSeq2000, or
HiSeq2500 platform.

24

25 2.3 Sequencing data analysis

Reads that passed quality control were mapped to the reference genome (UCSC Genome Browser assembly GRCh37/hg19, http://genome.ucsc.edu/) with a Burrows-Wheeler Aligner, v. 0.5.9.

1	Potential PCR duplicates were flagged with Picard MarkDuplicates, v. 1.88
2	(http://picard.sourceforge.net/). Genome Analysis Toolkit v. 2.2-8, was used to perform map quality
3	score recalibration and variant detection. Single nucleotide variants (SNVs) and indels were then
4	annotated for functional consequences at the gene using the ANNOVAR. Predictions of variants with
5	risk were also performed using ANNOVAR, with non-synonymous variants (LJB, v. 3.0) employed
6	for the effects on protein function (SIFT, PolyPhen, MutationTaster, Muration Assesor, LRT,
7	FATHMM) and evolutional conservation (GERP++, phyloP, Siphy). Criteria used for deleterious
8	variants in each prediction are shown following:
9	SIFT (sift): D: deleterious, PolyPhen 2 HDIV: D: Probably damaging, LRT: D: Deleterious,
10	MutationTaster: A (disease_causing_automatic) or D (disease_causing), MutationAssessor: H: high
11	FATHMM: D: deleterious, GERP++>5, phyloP>2.0, SiPhy>15
12	
13	2.4 Confirmation of SNVs
14	For PCR and sequencing (Greiner Bio-one) of the SNV of CRHR2, forward
15	(CCTGGCAGGGGGGAGAAGAGC) and reverse (CCCCAAGCTGCCTCCTGACA) primers, and
16	for the SNV of GRM8, forward (GCAACTCCAAGTCATCCATTTTCTTCA) and reverse
17	(TGGAGCGAATTGCTCGGGATT) primers, were used. Sequencing reactions were carried out
18	using a BigDye Terminator Cycle Sequencing kit, v. 3.1 (Thermo Fisher Scientific). Automated
19	electrophoresis was performed with an ABI PRISM 3730 Genetic Analyzer (Thermo Fisher
20	Scientific).
21	
22	3. Results
23	
24	3.1 WES
25	We obtained rare 4,032 SNVs, 113 splice site variants and 76 insertion/deletion variants (allele
26	frequency <0.001) from a total of 633,030 variants (Fig. 2). Initially, we attempted to identify
27	recessive and compound variants concordant with the affected sib-pairs, however none were found

among these rare variants. Next, heterozygote variants concordant with affected sib-pairs were
 extracted as dominant candidates. Finally, we estimated the most deleterious SNV in each family by
 use of six functional prediction (SIFT, PolyPhen, MutationTaster, Muration Assesor, LRT,
 FATHMM) and three conservation-based (GERP++, phyloP, Siphy) methods [9].

5 A previous large exome sequencing study indicated a strong inverse relationship between average 6 SNV age and number of methods needed to predict a variant as deleterious, thus SNVs predicted to 7 be deleterious by multiple methods probably undergo a more intense purifying selection and are very 8 rare in populations [10], suggesting them as candidates for disease pathogenesis. Moreover, most 9 very-rare variants arose within the past 5–10,000 years and are population-specific [11]. Therefore, 10 381 SNVs and 4 *de novo* SNVs were evaluated (Fig. 2, Supplementary Table 2) based on the 11 number of methods that predicted a variant to be deleterious and a feature of the gene. Among those, 12only two were predicted to be deleterious by all nine methods, an SNV in corticotropin releasing 13hormone receptor 2 (CRHR2) noted in family P15 and an SNV in glutamate metabotropic receptor 8 14 (GRM8) noted in family P4 (Table 1 and Fig.1-2). These were considered likely to be specific for a 15Japanese population, though a single allele for *CRHR2* was previously observed in Europeans (**Table** 16 1). In addition, SNVs supported by eight of the methods were observed in the P7, P8, and P11 17 families, while those supported by seven of the methods were observed in the P3 and P5 families. 18 the 10 CRHR2, GRM8, glutamate ionotropic Among genes, and receptor 19 α -amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) type subunit 2 (*GRIA2*) were 20 indicated to have higher levels of expression in the brain and related tissues (Table. 1).

21

6

Gene No. o						Substitution		Free	quency			
Gene	Family	No. of methods ^a	Chr	Position ^b	Alt ^c	Amino acid	SNV	Japanese ^d	European ^e (non-Finnish)	Gene description	Gene expression ^f	
CRHR2	P15	9	7	30702316	Т	p.G231R	rs569607645	0.000414	0.000009	Corticotropin-releasing hormone receptor 2	Pituitary, brain	
GRM8	P4	9	7	126409942	С	p.Y445C	NA	0.000000	0.000000	Glutamate metabotropic receptor 8	Testis, brain	
LGR4		8	11	27390603	С	p.N556S	rs754383451	0.000000	0.000016	Leucine-rich repeat-containing G	Ovary, pancreas	
MYH7B	P7	8	20	33583163	А	p.E951K	rs370896124	0.000535	0.000008	Myosin heavy chain 7B	Heart, skeletal muscle	
POC1B		8	12	89866042	Т	p.D155N	NA	0.000826	0.000000	POC1 centriolar protein homolog B	Heart, testis	
ACADS	Р8	8	12	121176662	Т	p.R325W	rs121908006	0.000000	0.000026	Acyl-CoA dehydrogenase, C-2 to C-3 short chain	Liver, skeletal muscle	
ALASI	P11	8	3	52236598	Т	p.P92L	rs370171958	0.000826	0.000015	Aminolevulinate, delta-, synthase 1	Adrenal gland, brain	
C3orf70	D2	-	3	184800841	1 A	p.S236L	rs201783027	s201783027 0.000413	0.000031	Chromosome 3 open reading frame 70	Colon, artery	
NRIP1	P3		21	16338385	Т	p.R710H	rs139218138	0.000000	0.000008	Nuclear receptor interacting protein 1	Cervix, adipose	
GRIA2	P5	7	4	158253975	Т	p.T296I	rs200845438	0.000400	0.000015	Glutamate receptor, ionotropic, AMPA 2	Brain, pituitary	

Abbreviations: NA, not applicable, ^aMaximum number of methods for predicting variant as deleterious in each family, ^bPhysical position in UCSC Genome Browser in Human Feb. 2009 Human GRCh37/hg19 Assembly, ^cAllele observed in this study, ^dAllele frequency in Japanese in Human Genetic Variation Database (<u>https://www.hgvd.genome.med.kyoto-u.ac.jp/</u>), ^eAllele frequency in European gnomAD (<u>https://gnomad.broadinstitute.org/</u>), ^fTop two tissues showing highest expression level in GTEx (release V8, 54 non-diseased tissue sites across nearly 1000 individuals).

1

2 CRHR2 encodes a neuropeptide receptor for corticotropin-releasing factor (CRF), a critical 3 coordinator of the hypothalamic-pituitary-adrenal axis [12] and for three urocortins (UCN1-UCN3) 4 [13]. CRHR2 is also a specific receptor for UCN2 and 3, which are associated with regulation of 5 stress, anxiety, and food intake [14-17]. GRM8 encodes a G-protein coupled metabotropic glutamate 6 receptor that influences inhibition of the cyclic AMP cascade and regulates presynaptic glutamate 7 release [18], and also has been found to have genetic associations with psychiatric phenotypes, 8 including depression [19, 20] and eating behavior [18]. The two variants were also confirmed by 9 Sanger sequencing (Supplementary Figure 1). Thus, it is considered that CRHR2 and GRM8 are 10 potent candidate genes due to the pathogenesis of EDs in individuals included in this study.

GRIA2 has a significant role in excitatory neurotransmission [21], and has been identified as a causative gene of intellectual disability and developmental epileptic encephalopathy. Therefore, we considered that *GRIA2* was a weaker candidate gene for EDs in this study, as the phenotypes generated by mutations may not be concordant with EDs. Furthermore, among the 381 SNVs considered to be candidates for dominant, all other SNVs were thought to be unlikely as causative factors of EDs after considering the descriptions and locations of expression (**Table 1**).

Four *de novo*, five splice site SNVs, and five insertion and deletion variants concordant with affected sib-pairs were identified as heterogeneous (Supplementary **Table 3 - 5**). However, in consideration of their features, these fourteen genes are unlikely to be causative factors of EDs.

20

21 3.2 Evaluation of impact of SNVs on CRHR2 and GRM8

CRHR2 is classified as a secretin subfamily among class B G protein-coupled receptors (GPCRs). A GPCR features seven transmembrane helices (TM), three extracellular loops, and three intracellular loops. The rare SNV in family P15 (rs569607645) was found located within the TM4 region. Gly 231, with a codon corresponding with the SNV conserved across species and among the class B GPCRs (**Fig. 3**), and located within a highly conserved sequence motif, GWGxP, in class B GPCRs [22]. Moreover, the substitution converts hydrophobic (glycine) into hydrophilic (arginine) amino

1 acid, implying that this SNV influences conformation and function of CRHR2.

2 Metabotropic glutamate (mGlu) receptors are members of the class C family of GPCRs that 3 modulate cellular responses to the excitatory neurotransmitter L-glutamic acid (L-Glu) in many 4 synapses in the CNS [23]. The amino terminal domain (ATD) of mGlu receptors contains an 5 orthosteric glutamate recognition site, which is highly conserved across the eight mGlu receptor 6 subtypes [24]. The rare SNV in family P4 was located within an α -helix structure of the ATD region. 7 Tyrosine 441, with a codon corresponding with the SNV, was found to be conserved across species 8 and hydrogen bonds to Asp 422 in an adjacent α -helix structure (Supplementary Figure 2) [23]. 9 Therefore, the substitution of tryptophan to cysteine is likely to cancel the hydrogen bond. We also 10 evaluated the effect of the SNV on protein stability using X-ray crystal structure data (PDB ID 11 6BSZ) and ENCoM, which are used to predict the effect of mutations on thermostability and 12 dynamics, as well as to generate geometrically realistic conformational ensembles [25]. Those 13results indicated that the conformation of GRM8 was expected to be destabilized (-0.822 kcal/mol). 14 Thus, the substitution may have an impact on the structure and functions of GRM8.

15

16 4. Discussion

17 4.1 CRHR2

Common SNVs in *CRHR2* were not detected in a large genome-wide association study for anorexia nervosa and other psychiatric disorders [4]. On the other hand, WES with bipolar disorder families identified a rare and functionally relevant nonsense variant within the intracellular C-terminal region of *CRHR2* [26]. Thus, it is suggested that a rare SNV in *CRHR2* contributes to the pathogenesis of a psychiatric disorder.

A study that used *Crhr2* knockout mice demonstrated that CRHR2 is essential for sustained feeding suppression induced by UCNs, members of the CRF family of peptides [27]. In another investigation, *Crhr2*-mutant mice showed decreased food intake following food deprivation [12]. Therefore, UCNs are potent for suppression of food intake by CRHR2-specific mediation [28]. Furthermore, *Crhr2*-mutant mice were also reported to have an anxiogenic phenotype and impaired

1 stress recovery [13]. These observations are related to serotoninergic neurons. Serotonin (5-HT) is 2 produced by serotoninergic neurons of the dorsal raphe nucleus (DRN) located within the brain stem 3 and regulates feeding behavior [29], while CRHR2 is specifically expressed in the DRN 4 serotoninergic neuron of [30] and plays important roles in controlling serotonergic neuronal activity 5 [31]. Hammack et al. performed experiments within the rat DRN using UCN2, an agonist for the 6 highly selective CRHR2, as well as an antagonist for that and demonstrated that CRHR2 in the DRN 7 mediates behavioral consequences of uncontrollable stress [32]. Additionally, anxiety-related stimuli 8 by UCN2 were shown to lead to increased activation of serotonergic neurons within the DRN [33]. 9 The DRN projects to the bed nucleus of the stria terminalis, which plays essential roles in threat 10 processing, and is responsible for such emotional states as fear and anxiety [34, 35]. The tone of the 11 DRN-5-HT system is regulated in a dynamic manner through CRHR2 activation, and either 12decreased or increased depending on the level of endogenous or exogenous ligands [36]. Indeed, in 13malnourished individuals suffering from AN the cerebrospinal fluid has reduced amounts of 14 5-hydroxyindoleacetic acid which is the major brain metabolite of 5-HT and is thought to reflect 15extracellular 5-HT concentrations, indicating that abnormal activity of 5-HT system is related to EDs 16 pathogenesis. [37]. Thus, CRHR2 mediates not only food intake, but also passive coping behavior 17 and depression-like responses triggered by uncontrollable stress [13] via the serotoninergic neuron in 18 the DRN.

19 Structural analysis demonstrated that the motif included with rs569607645 is a 20 cholesterol-binding site, and that artificial mutations in that site reduce the activation potency of 21 UCN1 and CRF to CRHR2, suggesting that the site plays a role in stabilizing peptide binding [38]. 22 Moreover, bound cholesterols in the structure of CRHR2 contribute to GPCR signaling, indicating 23that the GPCR signalosome carries out its function in the cholesterol-rich lipid raft [38]. Thus, the 24 substitution of G231R provided by the rare SNV rs569607645 impairs the functions of CRHR2, which may decrease the coping mechanism in response to stress [13] and/or feed suppression [28] in 2526 patients with EDs.



ED patients have higher rates of anxiety disorders as compared with normal individuals,

suggesting that both disorders might share common etiological factors, which can increase the susceptibility of an individual to either [39]. Stress is prominently involved in the pathogenesis and development of EDs and anxiety disorders. Moreover, coping mechanisms such as a positive attitude, planning, and social support seem to be impaired in ED patients who often do not cope well with emotional distress, implicating that such mechanisms may be disrupted [40]. Therefore, a decay of CRHR2 functions may play a part in the pathogenesis of EDs.

7

8 4.2 GRM8

As mentioned above, associations between psychiatric disorders and *GRM8* has been indicated with strong evidence in previous reports. On the other hand, a sequencing study for bipolar disorder identified enrichment of damaging mutations in GPCRs including *CRHR2* and the *GRM* gene family, with increased numbers of deleterious variants [26].

The mGluRs modulate glutamatergic neurotransmission, and are considered to also have effects on dopaminergic and adrenergic neurotransmission, implicating their involvement in a number of neurological disorders [41]. An expression study using animals indicated that GRM8 may play a role in feeding behavior and metabolism via the hypothalamic pathway [18, 42].

17

18 5 Conclusions

19 We found two rare SNVs as candidates for predisposition to EDs in affected sib-pair families. One 20 found located on CRHR2 plays important roles in the serotoninergic system in the DRN, and is 21 involved with feeding and stress-coping behavior, while the other SNV is located on GRM8, which 22 modulates cellular responses to the excitatory neurotransmitter in the CNS, and may play a role in 23feeding behavior and metabolism via the hypothalamic pathway. Moreover, the present findings 24 indicated potential for both non-synonymous SNVs to have impact on conformation and functions of 25molecules. However, this study only observed the deleterious SNVs in one family for each gene and 26 was not able to indicate that the SNVs explained how much of the genetic variance of EDs. 27 Furthermore, it is impossible to rule out all candidate variants. Therefore, these genes must be

- 1 confirmed by genetic analysis for additional families and sporadic cases and by functional analysis
- 2 in the future investigations.
- 3

4 Data accessibility

- 5 Data obtained in this study are available from the authors upon reasonable request.
- 6

7 Author contributions

- 8 AO conceived the studies, performed experiments, contributed to the data analysis, and drafted the
- 9 manuscript. SH, MU and SN were contributed to the data analysis. GK and TA were involved in
- 10 sample collection, editing the manuscript.

11

12 Funding

- 13 This work was supported by JSPS KAKENHI (16K09275 and 23390191).
- 14

15 **References**

- 16
- 17 [1] C.M. Bulik, L.M. Thornton, T.L. Root, et al., Understanding the relation between anorexia nervosa
- and bulimia nervosa in a Swedish national twin sample, Biol Psychiatry, 67 (2010) 71-77.
- 19 [2] M. Strober, R. Freeman, C. Lampert, et al., Controlled family study of anorexia nervosa and bulimia
- 20 nervosa: evidence of shared liability and transmission of partial syndromes, The American journal of
- 21 psychiatry, 157 (2000) 393-401.
- 22 [3] H. Cui, J. Moore, S.S. Ashimi, et al., Eating disorder predisposition is associated with ESRRA and
- HDAC4 mutations, The Journal of clinical investigation, 123 (2013) 4706-4713.
- [4] H.J. Watson, Z. Yilmaz, L.M. Thornton, et al., Genome-wide association study identifies eight risk
- loci and implicates metabo-psychiatric origins for anorexia nervosa, Nature genetics, 51 (2019)
 1207-1214.
- [5] H. Cui, Y. Lu, M.Z. Khan, et al., Behavioral disturbances in estrogen-related receptor alpha-null mice,
- 28 Cell reports, 11 (2015) 344-350.
- 29 [6] M. Lutter, M.Z. Khan, K. Satio, et al., The Eating-Disorder Associated HDAC4(A778T) Mutation
- 30 Alters Feeding Behaviors in Female Mice, Biol Psychiatry, 81 (2017) 770-777.
- 31 [7] K.C. Davis, K. Saito, S.R. Rodeghiero, et al., Behavioral Alterations in Mice Carrying Homozygous

1 HDAC4 (A778T) Missense Mutation Associated With Eating Disorder, Frontiers in neuroscience, 14

- 3 [8] D.E. Grice, K.A. Halmi, M.M. Fichter, et al., Evidence for a susceptibility gene for anorexia nervosa
- 4 on chromosome 1, Am J Hum Genet, 70 (2002) 787-792.
- 5 [9] X. Liu, X. Jian, E. Boerwinkle, dbNSFP v2.0: a database of human non-synonymous SNVs and their
- 6 functional predictions and annotations, Human mutation, 34 (2013) E2393-2402.
- 7 [10] W. Fu, T.D. O'Connor, G. Jun, et al., Analysis of 6,515 exomes reveals the recent origin of most
- 8 human protein-coding variants, Nature, 493 (2013) 216-220.
- 9 [11] M. Nagasaki, J. Yasuda, F. Katsuoka, et al., Rare variant discovery by deep whole-genome
- 10 sequencing of 1,070 Japanese individuals, Nature communications, 6 (2015) 8018.
- 11 [12] T.L. Bale, A. Contarino, G.W. Smith, et al., Mice deficient for corticotropin-releasing hormone
- receptor-2 display anxiety-like behaviour and are hypersensitive to stress, Nature genetics, 24 (2000)
 410-414.
- [13] M.J. Henckens, J.M. Deussing, A. Chen, Region-specific roles of the corticotropin-releasing
 factor-urocortin system in stress, Nature reviews. Neuroscience, 17 (2016) 636-651.
- 16 [14] C. Yeh, C.H. Ting, M.L. Doong, et al., Intracerebroventricular urocortin 3 counteracts central acyl
- ghrelin-induced hyperphagic and gastroprokinetic effects via CRF receptor 2 in rats, Drug design,
 development and therapy, 10 (2016) 3281-3290.
- 19 [15] P. Cottone, V. Sabino, T.R. Nagy, et al., Centrally administered urocortin 2 decreases gorging on
- high-fat diet in both diet-induced obesity-prone and -resistant rats, International journal of obesity (2005),
- 21 37 (2013) 1515-1523.
- 22 [16] T.M. Reyes, K. Lewis, M.H. Perrin, et al., Urocortin II: a member of the corticotropin-releasing
- 23 factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors, Proceedings of the
- 24 National Academy of Sciences of the United States of America, 98 (2001) 2843-2848.
- 25 [17] K. Lewis, C. Li, M.H. Perrin, et al., Identification of urocortin III, an additional member of the
- 26 corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor, Proceedings of the
- 27 National Academy of Sciences of the United States of America, 98 (2001) 7570-7575.
- [18] M.T. Gast, A. Tonjes, M. Keller, et al., The role of rs2237781 within GRM8 in eating behavior, Brain
 Behav, 3 (2013) 495-502.
- [19] A. Terracciano, T. Tanaka, A.R. Sutin, et al., Genome-wide association scan of trait depression, Biol
 Psychiatry, 68 (2010) 811-817.
- 32 [20] W. Li, K. Ju, Z. Li, et al., Significant association of GRM7 and GRM8 genes with schizophrenia and
- major depressive disorder in the Han Chinese population, Eur Neuropsychopharmacol, 26 (2016)
 136-146.
- 35 [21] D. Capauto, A. Colantoni, L. Lu, et al., A Regulatory Circuitry Between Gria2, miR-409, and
- 36 miR-495 Is Affected by ALS FUS Mutation in ESC-Derived Motor Neurons, Molecular neurobiology, 55
- 37 (2018) 7635-7651.

^{2 (2020) 139.}

- 1 [22] K. Hollenstein, J. Kean, A. Bortolato, et al., Structure of class B GPCR corticotropin-releasing factor
- 2 receptor 1, Nature, 499 (2013) 438-443.
- 3 [23] Q. Chen, J.D. Ho, S. Ashok, et al., Structural Basis for (S)-3,4-Dicarboxyphenylglycine (DCPG) As
- 4 a Potent and Subtype Selective Agonist of the mGlu(8) Receptor, Journal of medicinal chemistry, 61
- 5 (2018) 10040-10052.
- 6 [24] J. Hao, Q. Chen, Insights into the Structural Aspects of the mGlu Receptor Orthosteric Binding Site,
- 7 Current topics in medicinal chemistry, 19 (2019) 2421-2446.
- 8 [25] V. Frappier, M. Chartier, R.J. Najmanovich, ENCoM server: exploring protein conformational space
- 9 and the effect of mutations on protein function and stability, Nucleic acids research, 43 (2015) W395-400.
- 10 [26] C. Cruceanu, J.F. Schmouth, S.G. Torres-Platas, et al., Rare susceptibility variants for bipolar
- disorder suggest a role for G protein-coupled receptors, Mol Psychiatry, 23 (2018) 2050-2056.
- 12 [27] S.C. Coste, R.A. Kesterson, K.A. Heldwein, et al., Abnormal adaptations to stress and impaired
- 13 cardiovascular function in mice lacking corticotropin-releasing hormone receptor-2, Nature genetics, 24
- 14 (2000) 403-409.
- 15 [28] W. Pan, A.J. Kastin, Urocortin and the brain, Progress in neurobiology, 84 (2008) 148-156.
- 16 [29] C.P. Magalhães, M.F. de Freitas, M.I. Nogueira, et al., Modulatory role of serotonin on feeding
- 17 behavior, Nutritional neuroscience, 13 (2010) 246-255.
- 18 [30] J. Ren, A. Isakova, D. Friedmann, et al., Single-cell transcriptomes and whole-brain projections of
- 19 serotonin neurons in the mouse dorsal and median raphe nuclei, eLife, 8 (2019).
- [31] M.W. Lieb, M. Weidner, M.R. Arnold, et al., Effects of maternal separation on serotonergic systems
- in the dorsal and median raphe nuclei of adult male Tph2-deficient mice, Behavioural brain research, 373
- 22 (2019) 112086.
- 23 [32] S.E. Hammack, M.J. Schmid, M.L. LoPresti, et al., Corticotropin releasing hormone type 2 receptors
- in the dorsal raphe nucleus mediate the behavioral consequences of uncontrollable stress, The Journal of
 neuroscience : the official journal of the Society for Neuroscience, 23 (2003) 1019-1025.
- 26 [33] J.H. Fox, C.A. Lowry, Corticotropin-releasing factor-related peptides, serotonergic systems, and
- emotional behavior, Frontiers in neuroscience, 7 (2013) 169.
- 28 [34] S. Ueda, M. Hosokawa, K. Arikawa, et al., Distinctive Regulation of Emotional Behaviors and
- 29 Fear-Related Gene Expression Responses in Two Extended Amygdala Subnuclei With Similar Molecular
- 30 Profiles, Frontiers in molecular neuroscience, 14 (2021) 741895.
- 31 [35] C.A. Marcinkiewcz, G. Bierlein-De La Rosa, C.E. Dorrier, et al., Sex-Dependent Modulation of
- 32 Anxiety and Fear by 5-HT(1A) Receptors in the Bed Nucleus of the Stria Terminalis, ACS chemical
- 33 neuroscience, 10 (2019) 3154-3166.
- 34 [36] L. Pernar, A.L. Curtis, W.W. Vale, et al., Selective activation of corticotropin-releasing factor-2
- 35 receptors on neurochemically identified neurons in the rat dorsal raphe nucleus reveals dual actions, The
- 36 Journal of neuroscience : the official journal of the Society for Neuroscience, 24 (2004) 1305-1311.
- 37 [37] W.H. Kaye, J.L. Fudge, M. Paulus, New insights into symptoms and neurocircuit function of

- 1 anorexia nervosa, Nature reviews. Neuroscience, 10 (2009) 573-584.
- 2 [38] S. Ma, Q. Shen, L.H. Zhao, et al., Molecular Basis for Hormone Recognition and Activation of
- 3 Corticotropin-Releasing Factor Receptors, Molecular cell, 77 (2020) 669-680.e664.
- 4 [39] E. Pallister, G. Waller, Anxiety in the eating disorders: understanding the overlap, Clinical
- 5 psychology review, 28 (2008) 366-386.
- 6 [40] N.T. Burkert, K. Koschutnig, F. Ebner, et al., Structural hippocampal alterations, perceived stress,
- and coping deficiencies in patients with anorexia nervosa, The International journal of eating disorders,
 48 (2015) 670-676.
- 9 [41] J.-Q. Wang, A.-L. Brownell, Development of Metabotropic Glutamate Receptor Ligands for
- 10 Neuroimaging, Current Medical Imaging Reviews, 3 (2007) 186-205.
- 11 [42] S.E. Higgins, L.E. Ellestad, N. Trakooljul, et al., Transcriptional and pathway analysis in the
- hypothalamus of newly hatched chicks during fasting and delayed feeding, BMC genomics, 11 (2010)162.
- 14

15 FIGURE LEGENDS

- 16
- 17 FIGURE 1 Sib-pair families affected by EDs were examined using whole exome sequencing.
- 18 Individuals labeled with an ID number were sequenced. The disease phenotype of affected sib-pairs
- 19 in the P15 family was transferred from ANR to BN. The rare variants GRM8 and CRHR2 were
- 20 observed in the P4 and P15 families, respectively.
- 21 Abbreviations: ANR, anorexia nervosa restricting type BN, bulimia nervosa

22

- 23 **FIGURE 2** Scheme for screening variants with whole exome sequencing.
- 24
- 25
- FIGURE 3 Multiple amino acid sequence alignments of TM4 helix of human class B GPCRs and CRHR2 in various species. Upper alignment indicates TM4 of a selected set of human class B GPCRs included with the GWG x P motif involved in cholesterol binding. Lower alignment indicates evolutionarily conserved amino acids. The level of blue shading is shown according to sequence conservation. Black square indicates amino acid position corresponding to human G231.

31



Figure 1



Figure 2



Figure 3



Supplementary Figure 1

Confirmation by Sanger sequencing for SNVs. Red squares indicate codons providing amino acid substitutions. Upper panel shows SNV of CRHR2 in P15 family. Lower panel shows SNV of GRM8 in P4 family.



Supplementary Figure 2

Multiple amino acid sequence alignment of GRM8 showing evolutionarily conserved amino acids and ATD structure of GRM8. Upper alignment indicates evolutionarily conserved amino acids. Black square indicates amino acid position corresponding to human Y445. Middle panel indicates ribbon diagram around Y445 (light green). Hydrogen bonds are depicted as blue dotted lines. Lower panel indicates ribbon representation for all ATDs including Y445 (light green). These ribbon diagram images were created using Mol* Viewer [1] with the PROTEIN DATA BANK (https://www.rcsb.org/) for PDB ID 6BSZ [2].

- [1] D. Sehnal, S. Bittrich, M. Deshpande, et al., Mol* Viewer: modern web app for 3D visualization and analysis of large biomolecular structures, Nucleic acids research, 49 (2021) W431-w437.
- [2] Q. Chen, J.D. Ho, S. Ashok, et al., Structural Basis for (S)-3,4-Dicarboxyphenylglycine (DCPG) As a Potent and Subtype Selective Agonist of the mGlu(8) Receptor, Journal of medicinal chemistry, 61 (2018) 10040-10052.

medRxiv preprint doi: https://doi.org/10.1101/2023.08.24.23294455; this version posted August 25, 2023. The copyright holder for this preprint Supplementary Table by Charles in the supplementary of the supplementary of

Family ID	Individual ID	Gender	Subtype through	Height	Weig	ht (kg)
T anniy ID		Genuer	lifetime	(cm)	Min.	Max.
D 2	P3-1	F	ANR	158	NA	NA
PJ	P3-2	F	ANR	151	NA	NA
D4	P4-1	F	BN	156	NA	NA
P4	P4-2	F	BN	161	NA	NA
DE	P5-1	F	ANR	156	28	NA
PD	P5-2	F	ANR	167	44	58
DZ	P7-1	F	BN	162	NA	NA
Ρ7	P7-2	F	BN	158	43	60
	P8-1	F	BN	152	NA	NA
P8	P8-2	F	BN	160	39	53
	P8-3	М	ANR	169	42	53
D44	P11-1	F	ANR	162	26	64
PII	P11-2	F	ANR	168	33	52
D4C	P15-1	F	ANR→BN	162	33	57
P15	P15-2	F	ANR→BN	168	40	47

(which was	not certifi	ed by peer 1	review) is	the autho	r/funder, who	has granted	t.medRxi	v a license to dis	play the prepri	nt in perpeti	
Gene symbol	Chr	Position ^a	lt _{rise} ma	de availab	le under a CC	C-BY 4.0 Hts	mationa	license.	SNV	Frequency ^d	INO. OF
	0	1 0311011		ar ar	cDNA	Amino acid	Exon	Transcript ID	0.11	ricqueriey	methods ^e
FAM213B	1	2518564	С	Т	c.C188T	p.A63V	exon2	NM 001195736	NA	0.000000	2
PRDM16	1	3342747	Ċ	А	c C3242A	n A1081D	exon14	NM 022114	NA	0 000000	5
MEGE6	1	3/07118	Ğ	^	c C4600T	p.7(1001D	000037	NM_001400	NA	0.000000	2
NILGI U	1	0704004	9	~	0.040001	p.it 1334W	6201137			0.000000	2
	1	3/64001	G	A T	C.G500A	p.K109Q	exon4	INIVI_001262669	15201973416	0.000415	7
C1orf167	1	11835556	С	I	c.C20531	p.R685C	exon9	NM_001010881	rs41275456	0.000000	0
C1orf167	1	11838841	A	G	c.A2464G	p.S822G	exon11	NM_001010881	rs56001051	0.000000	0
C1orf167	1	11839034	G	А	c.G2548A	p.A850T	exon12	NM 001010881	rs55967531	0.000000	0
C1orf167	1	11845222	т	С	c T3443C	n V1148A	exon16	NM_001010881	rs55867221	0 000000	0
C1orf167	1	110/7//0	Ċ	^	0.101100	p.01101U	oxon17	NIM_001010001	ro2727067	0.000000	õ
010/1107		11647449	G	A	C.G3572A	p.K1191H	exon17	NIVI_001010861	153737967	0.000000	0
C1orf167	1	11848068	G	С	c.G3812C	p.C1271S	exon18	NM_001010881	rs1537514	0.000000	0
VPS13D	1	12309316	G	A	c.G484A	p.G162S	exon6	NM_015378	NA	0.000000	2
PADI1	1	17559348	С	Т	c.C1196T	p.P399L	exon11	NM 013358	NA	0.000000	0
ΔΙ ΡΙ	1	2100/1130	Ġ	Δ	c G1333A	n \/4451	evon10	NM 001177520	ΝΔ	0 000000	1
	1	21304100	č	л т	0.01000/(p. 07400	oxon17	NM_001201960	NIA	0.000000	2
HSPG2		22206699	G	<u> </u>	C.C2247A	p.n/49Q	exoni7	INIVI_001291660	INA	0.000413	2
KIAA0754	1	39879446	C	I	c.C35091	p.A1170V	exon1	NM_015038	NA	0.000828	0
CCDC30	1	43047046	С	Т	c.C1081T	p.R361W	exon8	NM_001080850	NA	0.000000	4
HOOK1	1	60314066	С	Т	c.C1009T	p.R337C	exon11	NM 015888	NA	0.000829	6
DOCKZ	1	63050524	G	Α	c C1826T	p P609I	exon16	NM 001272002	NA	0 000000	0
II 22P	1	67705022	č	С С	0.010201	p.1 000E	0,0000	NM 144701	ro100542422	0.000414	e
ILZSR	1	07705932	Ğ	÷		p.L372F	exona	NIVI_144701	15199042400	0.000414	0
IL23R	1	67705933	A	I	C.A11171	p.1373F	exon9	NM_144701	rs201752419	0.000414	3
C1orf146	1	92709776	G	A	c.G163A	p.V55I	exon4	NM_001012425	NA	0.000000	2
CD101	1	117556339	А	G	c.A1153G	p.T385A	exon4	NM 001256106	NA	0.000428	0
HFF2	1	145416517	С	т	c C184T	p R62W	exon2	NM 213652	NA	0 000000	8
MPPLO	1	151735917	Ğ	^	c C120T	n147E	oxon1	NM 001300733	NA	0.000414	4
MRFL9	1	151755617	G	A T	0.01391	p.L47F	exonn	NIVI_001300733	INA NA	0.000414	4
NES	1	156639758	C	I	C.G4222A	p.E1408K	exon4	NM_006617	NA	0.000000	4
INSRR	1	156821447	G	A	c.C1075T	p.R359C	exon4	NM_014215	NA	0.000413	6
OR10R2	1	158449783	G	А	c.G116A	p.S39N	exon1	NM 001004472	rs139828408	0.000000	1
PYHIN1	1	158908991	С	G	c C533G	n P178R	exon4	NM 152501	rs79928064	0 000000	0
	1	161019556	č	č	0.00000	p.1 1701	cxon ⁹	NIM_001297602	NIA	0.000000	0
ARHGAFSU	1	101010000	C	G	0.017240	p.K5751	exuno	NIVI_001207002	INA	0.000000	0
NOS1AP	1	162313766	G	A	c.G580A	p.G194S	exon6	NM_001164757	NA	0.000000	3
SELL	1	169677900	A	G	c.T169C	p.S57P	exon3	NM_000655	NA	0.000000	5
SUCO	1	172501689	G	С	c.G77C	p.G26A	exon1	NM 016227	NA	0.000000	1
TOR3A	1	179054915	Ğ	A	c G526A	n V176M	exon3	NM_022371	NA	0 000000	3
SMC7	1	102515464	Č	л т	0.00200T	p.01700	0/00/10	NM 001174061	NIA	0.000545	2
31/107	1	100010404	C	т Т	0.020001	p.F6703	exonito	NIVI_001174001	INA	0.000345	3
CFH	1	196709910	C	I	C.C29441	p.P982S	exon18	NM_000186	rs149938052	0.000828	8
PIK3C2B	1	204408074	С	Т	c.G3505A	p.E1169K	exon24	NM_002646	rs143689889	0.000000	5
FLVCR1	1	213031874	G	С	c.G80C	p.R27T	exon1	NM 014053	NA	0.000910	1
KCNK2	1	215408418	G	Α	c G1199A	n S400N	exon7	NM 001017424	rs76873069	0 000000	6
EDDS	1	220206040	Ť	C C	c A 202C	p.01001	oxon/	NM 004446	NIA	0.000000	2
EPRS	1	220200940	1	C	C.A292G	p.196A	ex0114	NIVI_004440	INA	0.000000	2
HLX	1	221053600	A	C	C.A401C	p.Q134P	exon1	NM_021958	rs201006102	0.000845	1
DNAH14	1	225211527	A	G	c.A1318G	p.M440V	exon11	NM_001145154	NA	0.000000	0
CDC42BPA	1	227216678	С	G	c.G3764C	p.R1255P	exon28	NM_014826	NA	0.000413	6
OBSCN	1	228402755	т	Δ	c T1784A	n E595Y	exon5	NM 001098623	NA	0 000000	2
IVST	1	225026144	Ċ	G	c C6120C	p.1 0001	020022	NM 000081	NA	0.000000	2
	1	233920144	C	9	0.001290	p.n2045N	exuitzz			0.000000	2
ACTN2	1	236906343	G	A	C.G1255A	p.G419S	exon11	NM_001103	NA	0.000414	6
KIF26B	1	245850232	С	Т	c.C3947T	p.S1316L	exon12	NM_018012	NA	0.000000	2
OR1C1	1	247921589	С	G	c.G120C	p.L40F	exon1	NM_012353	rs201462993	0.000000	0
WDR35	2	20138102	т	С	c.A1987G	p.S663G	exon18	NM 020779	NA	0.000826	5
APOR	2	21220457	Ġ	Ť	c C10283A	p T3/28N	020026	NM_000384	NA	0.000/13	0
AFOD	2	21229437	9	÷	C.C.10203A	p.13420N	6201120	NM_004000	114	0.000413	0
ADC Y3	2	25050816	C	1	C.G2387A	р.к/96н	exon13	NIVI_004036	18372560995	0.000413	2
HADHB	2	26502162	G	A	c.G745A	p.V249M	exon8	NM_001281512	NA	0.000413	1
SLC5A6	2	27430151	С	Т	c.G368A	p.R123H	exon3	NM_021095	rs188933728	0.000000	5
BIRC6	2	32727916	G	С	c G9262C	n V3088I	exon48	NM 016252	NA	0 000000	7
BIPC6	2	327/0551	Ğ	Ť	c G11063T	n R3688M	exon55	NM_016252	NΔ	0.000000	7
DINCO	2	4400007	0	÷	0.0110001	p.1000000	6201100			0.000000	,
DYNCZLII	2	44032327	C	1	C.C9381	p.A313V	exon12	NIVI_001193464	rs14/70/04/	0.000413	5
FANCL	2	58449116	G	A	c.C3351	p.S112L	exon5	NM_001114636	NA	0.000413	4
BCL11A	2	60688494	С	Т	c.G1553A	p.S518N	exon4	NM_018014	NA	0.000000	4
AFTPH	2	64779380	G	А	c.G772A	p.A258T	exon2	NM 001002243	NA	0.000826	0
EGR4	2	73519027	Ğ	Δ	c C1328T	n 4443V	exon2	NM 001965	NΔ	0.000000	0
	2	00074070	0		- 05004	- 1/400	CX0112	NIM_005705	NIA	0.000000	4
ACIRIB	2	96274979	C	<u> </u>	C.G506A	p.v1901	exono	INIVI_005735	INA	0.000000	4
DARS	2	136700968	C	I	c.G103A	p.V351	exon4	NM_001293312	rs140573664	0.000000	4
XIRP2	2	168103167	G	С	c.G4599C	p.L1533F	exon7	NM_001199144	NA	0.000000	4
PDE11A	2	178879115	G	А	c.C985T	p.R329X	exon2	NM 016953	rs188985665	0.000826	1
AOX1	2	201527649	С	т	c C3500T	n A1167V	exon31	NM_001159	rs35345784	0 000000	5
	2	201027043	č	^	0.000001	p.7(1107V		NIM_001126574	NIA	0.000000	0
LANCLI	2	211319034	G	A	0.04041	p.11351	620114	NIVI_001130374	INA	0.000000	0
CATIP	2	219232598	C	G	c.C1075G	p.P359A	exon10	NIVI_198559	NA	0.000414	0
MROH2A	2	234708903	A	т	c.A1511T	p.H504L	exon14	NM_001287395	rs140951259	0.000000	0
MROH2A	2	234740136	G	А	c.G4726A	p.A1576T	exon39	NM_001287395	rs879665	0.000000	0
COI 6A3	2	238275503	А	G	c.T3506C	p.V1169A	exon8	NM 057166	NA	0.000000	8
	- 2	24100000	~	т т	0.100000	n A000	0,000	NIM_000020	NIA	0.000000	5
AGAI	2	241000000	G	1	0.02051	h.4092	exunz		INA	0.000000	5
PASK	2	242066279	G	С	c.C2051G	p.P684R	exon10	NM_001252119	rs56372985	0.000827	1
PLCD1	3	38050766	A	G	c.T1666C	p.S556P	exon10	NM_001130964	NA	0.000000	3
SLC22A13	3	38316953	G	А	c.G899A	p.R300Q	exon5	NM 004256	rs145061420	0.000413	2
NME6	2	48338264	Δ	G	c T11C	nl4P	exon?	NM 001308/3/	ΝΔ	0 000000	6
	5	F0000204	~	9 -	0.1110	p.L+F		NIM_00100434	11/1	0.000000	0
ALAS1	3	52236598	U	I	c.C2/51	p.P92L	exon3	INIVI_001304443	153/01/1958	0.000826	8
CADPS	3	62467420	Т	С	c.A3151G	p.M1051V	exon22	NM_003716	NA	0.000000	5
ATXN7	3	63981783	С	т	c.C1850T	p.T617M	exon8	NM_001128149	rs368650687	0.000413	1
SUCLG2	3	67578623	G	А	c.C350T	p.A117V	exon4	NM 001177599	NA	0.000000	5
ORSKO	3	98100652	Ť	Δ	c T1/2A	n1/18Y	evon1	NM_001005516	NΔ	0 000826	2
0110110	5	00100002		~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	0.1170/1	P.L-10/	0.0011		1 1/ 1	0.000020	0

Supplementage Raik preprint doi: https://doi.org/10.1101/2023.08.24.23294455; this version posted August 25, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. No. of

_

energe z∧detexiv p	preprint doi: ₃ https was not certifie	:://doij.gr/g640 ed /2014.2008/140	.110 1 /2 evie<u>x</u>v)	023.08 ₆ 24.23 is the author/	<mark>2944555</mark> .dhi fup q q5 ₈ whc	s ver sig g _A pos has-gran <u>t</u> eo	sted Aug 1 med Rxi	ustina5₀&0283280596 va\lindenaso4tosdis	e copy rig ht hol play the∆prepri	der for this p int in persetu	reprinat uity. ⊿
ARHGAP31	3	119134525	lt is 'n	ade available	under a C	C-BY 4 0 Ate	ernătional exon12	license NM 020754	NA	0.000000	2
GPR156	3	119885889	G	A	c.C2423T	p.T808M	exon9	NM 001168271	rs200926939	0.000413	5
SEMA5B	3	122634697	С	Т	c.G1555A	p.G519R	exon12	NM_001256348	rs183425023	0.000000	0
UMPS	3	124456826	С	Т	c.C722T	p.S241L	exon3	NM_000373	NA	0.000000	2
COL6A5	3	130190716	G	A	c.G7765A	p.A2589T	exon40	NM_001278298	rs73868680	0.000000	1
HLTF	3	148778571	A	Т	c.T1235A	p.M412K	exon11	NM_003071	rs201653124	0.000000	1
ERICH6	3	150387158	G	A	C.C9861	p.P329L	exon12	NM_001308234	rs200581445	0.000413	1
GIVIPS SLC7A1A	3	122033905	G	G	c.11136G	p.L379R	exon9	NM 020040	NA NA	0.000000	5 7
USP13	3	179399676	G	C	c G179C	p.F467A	exon2	NM_003940	NA	0.000000	5
C3orf70	3	184800841	Ğ	Ă	c.C707T	p.S236L	exon2	NM 001025266	rs201783027	0.000413	7
SLC26A1	4	985463	Т	С	c.A29G	p.Q10R	exon2	NM_022042	NA	0.000439	1
FAM53A	4	1646051	С	Т	c.G901A	p.E301K	exon5	NM_001297435	NA	0.000000	0
HTT	4	3240332	Α	G	c.A9050G	p.Y3017C	exon65	NM_002111	NA	0.000000	3
TMEM128	4	4249884	G	T	c.C46A	p.L16I	exon1	NM_001297551	rs6854167	0.000000	0
WFS1	4	6302786	G	I	c.G12641	p.A422S	exon8	NM_001145853	NA	0.000413	4
LOC389199	4	7940903	A	G	C.ATTG	p.Q4R	exon1	NW_203423	rs7660645	0.000000	1
GPR78	4	8582821	Δ	C C	c A112C	p.ro⊑ n T38P	exon1	NM 080819	NΔ	0.000000	1
BMP2K	4	79747277	c	A	c.C265A	p.1891	exon2	NM 017593	NA	0.000414	6
HNRNPDL	4	83347711	C	G	c.G1097C	p.G366A	exon6	NM_031372	rs200123403	0.000826	6
SPARCL1	4	88403697	G	А	c.C1172T	p.T391M	exon6	NM_001291977	rs199501739	0.000000	4
ANK2	4	114288871	G	A	c.G4927A	p.V1643I	exon41	NM_020977	NA	0.000826	0
MAML3	4	140811296	G	A	c.C1294T	p.P432S	exon2	NM_018717	NA	0.000000	1
ELMOD2	4	141446643	C	G	c.C61G	p.L21V	exon2	NM_153702	rs201497167	0.000000	1
HHIP	4	145627795	A	G	c.A944G	p.H315R	exon5	NM_022475	NA	0.000000	6
PRM19	4	148575205	G	C	c.C1504G	p.H502D	exon8	NM_001304458	NA	0.000000	5
I RBA	4	140005000		G	c T2747C	p.v25⊑ n1916S	exon22	NM 001199282	ΝA	0.000000	4
TMFM154	4	153601028	C C	A	c G58T	p.E3100	exon1	NM 152680	NA	0.000000	1
GRIA2	4	158253975	č	Т	c.C887T	p.T296l	exon7	NM 000826	NA	0.000000	7
SH3RF1	4	170189972	С	G	c.G392C	p.R131T	exon2	NM_020870	rs200790356	0.000000	4
NEK1	4	170483332	С	A	c.G1036T	p.E346X	exon12	NM_001199400	NA	0.000000	1
SCRG1	4	174312559	G	С	c.C7G	p.L3V	exon2	NM_007281	NA	0.000829	0
CFAP97	4	186111851	С	Ť	c.G500A	p.C167Y	exon2	NM_001292033	rs182552516	0.000413	0
LRP2BP	4	186295608	C	I	c.G338A	p.G113E	exon4	NM_018409	NA	0.000413	7
	5	434450	A	G	C.A1613G	p.K538K	exon11	NM_015225	NA	0.000000	4
TRIO	5	14143940	G	C I	c G106C	p.111723	exon1	NM_007118	NA	0.000000	0
C5orf42	5	37167291	Ğ	Ă	c.C7258T	p.L2420F	exon35	NM 023073	NA	0.000000	4
ZSWIM6	5	60840041	С	т	c.C3545T	p.A1182V	exon14	NM_020928	NA	0.000000	6
MAST4	5	65892790	G	A	c.G307A	p.A103T	exon1	NM_001164664	NA	0.000000	0
ANKRD31	5	74491679	G	С	c.C794G	p.P265R	exon7	NM_001164443	rs185973227	0.000000	0
POLK	5	74886182	A	G	c.A1273G	p.1425V	exon11	NM_016218	NA	0.000000	2
SLF1	5	94014564	A	G	c.A1879G	p.1627V	exon15	NM_032290	NA	0.000000	0
EBND	5	122309000	r C	G	C.A541C	p.1101P	exon53	NM 001000	IS149059275	0.000826	2
FNIP1	5	131008060	C C	G	c G1993C	p.G22203	exon13	NM 001008738	NA	0.000000	1
P4HA2	5	131528750	Ğ	A	c.C1555T	p.R519X	exon15	NM 001017973	rs200583507	0.000414	4
PCDHGB2	5	140740144	č	Т	c.C442T	p.P148S	exon1	NM_018923	NA	0.000000	1
DPYSL3	5	146777371	С	Т	c.G1661A	p.R554H	exon12	NM_001197294	rs188735247	0.000000	5
RANBP17	5	170380604	G	A	c.G1472A	p.R491H	exon13	NM_022897	rs139638431	0.000000	6
VARS2	6	30892159	C	Т	c.C2075T	p.S692L	exon25	NM_001167733	rs138341222	0.000000	0
BIBD9	6	38256214	I	С	c.A1084G	p.1362V	exon7	NM_152733	NA	0.000000	3
DNAH8	6	38957803	A	G	C.A13069G	p.K4357E	exon88	NM_015090	IS139250593	0.000828	2
RRAGD	6	90121613	C.	G	c G100C	n G34R	exon1	NM 021244	NA	0.000000	∠ 3
SLC22A16	6	110746218	č	Ť	c.G1592A	p.R531Q	exon8	NM 033125	NA	0.000000	2
RSPH4A	6	116953437	C	т	c.C1984T	p.P662S	exon6	NM_001010892	NA	0.000000	6
STXBP5	6	147599259	А	G	c.A757G	p.I253V	exon8	NM_001127715	NA	0.000826	2
SYNE1	6	152674804	С	Т	c.G10957A	p.E3653K	exon68	NM_033071	NA	0.000000	6
TULP4	6	158850898	C	Т	c.C512T	p.T171M	exon3	NM_001007466	NA	0.000419	4
C7orf50	7	1040177	I	C	c.A334G	p.K112E	exon4	NM_001134395	NA	0.000837	1
USP42	7	0194357	A	1	C.A31721	p.K1058W	exon15	NW_032172	NA	0.000000	2
CRHR2	7	20739094	C	T	c G688A	p.G313D	exon6	NM 001202482	INA re560607645	0.000414	0 0
AMPH	7	38670924	c C	A	c G28T	p.02001	exon1	NM 001635	NA	0.00000	2
PKD1L1	7	47886553	Ă	G	c.T5077C	p.F1693L	exon32	NM 138295	NA	0.000000	0
ZNF117	7	64439432	С	т	c.G517A	p.A173T	exon4	NM_015852	NA	0.000000	0
ZSCAN21	7	99655438	G	А	c.G517A	p.E173K	exon3	NM_145914	NA	0.000000	3
AP4M1	7	99703902	G	С	c.G1013C	p.R338P	exon13	NM_004722	NA	0.000000	2
ORAI2	7	102087451	G	С	c.G486C	p.K162N	exon3	NM_001271819	NA	0.000000	2
GRM8	7	126409942	T	C	c.A1334G	p.Y445C	exon6	NM_000845	NA	0.000000	9
AUC1 ARCPP	/ 7	1505549/3	A	<u>ح</u>	C.A1415G	p.1N4725 p.1/330M	exon2	NIVI_001091	NA NA	0.000000	3
CHPF?	7	150929872	C	Ť	c C22T	p. v 330ivi n P8S	exon1	NM 001284295	rs374377560	0.000000	4
ADAM28	8	24178758	Ğ	Å	c.G676A	p.E226K	exon8	NM 001304351	NA	0.000000	0
ADAM7	8	24349579	Ğ	A	c.G1520A	p.R507H	exon14	NM_003817	NA	0.000000	4
PBK	8	27678103	G	т	c.C574A	p.P192T	exon6	NM_001278945	rs200662690	0.000826	1
ZFHX4	8	77762550	С	Т	c.C3916T	p.R1306W	exon9	NM_024721	NA	0.000414	1
ZFAND1	8	82626176	С	Т	c.G457A	p.D153N	exon6	NM_001170796	NA	0.000000	0

ZNFWhich was	not certifi 9	ed 424 poor 1000 role 10	eview) is It is mad	the author e available	/funderato	has granted -By 400 hte	d med Axi ernational	V ANICENSE 188808	play the prepri	ntdin perpetuity 0.000826	/. /
RIC1	9	5756326	Ğ	Å	c G1696A	n A566T	exon15	NM 001206557	rs145216888	0.000827	ļ
I HRE2	å	6421108	C C	Δ	c C350A	n A117D	exon2	NM 152896	NA	0.000000	
MPDZ	q	13222290	Č	т	c G689A	p.5230N	exon6	NM 001261406	NΔ	0.000000	
	9	15486844	т	Ċ	c A374G	p.0200N	exon4	NM 021144	NΔ	0.000000	
BNC2	9	16/36081	Ť	Č	c A2111G	p.E1200	evone	NM_017637	ΝΔ	0.000000	
DINUZ	9	10063005	T	G	c.A2111G	p.L7040		NM 001270800	rc1/7787866	0.000000	
NAU30	9	13003033		- т	0.A14330	p.1479Q	6X01114	NM_001270030	NIA	0.000000	
	9	27502432	C	Î	C.G547A	p.v 1631	ex0114	NIVI_001256054	INA NA	0.000422	
MEM8B	9	35842551	G	A	c.G116A	p.R39H	exon6	NM_001042590	NA	0.000000	
SHB	9	38068006	1	C	c.A63/G	p.1213A	exon1	NM_003028	NA	0.000880	
PRUNE2	9	79323007	С	Т	c.G4183A	p.E1395K	exon8	NM_001308047	NA	0.000000	
NOL8	9	95085735	С	Т	c.G190A	p.D64N	exon3	NM_017948	rs151033269	0.000827	
FBP2	9	97355952	С	Т	c.G57A	p.M19I	exon1	NM_003837	NA	0.000000	
ERCC6L2	9	98684666	С	Т	c.C1412T	p.A471V	exon8	NM_001010895	rs201546231	0.000829	
TBC1D2	9	100962538	С	Т	c.G1196A	p.S399N	exon6	NM_001267572	NA	0.000000	
GALNT12	9	101570348	С	Α	c.C368A	p.P123Q	exon1	NM_024642	NA	0.000000	
ARPC5L	9	127639182	С	G	c.C425G	p.S142C	exon4	NM 030978	rs150162831	0.000828	
-AM102A	9	130707095	Č	Ť	c G574A	p V192M	exon6	NM 203305	NA	0.000000	
SI C2744	å	131117070	Ť	Ċ	c T1678C	p.0102m	evon12	NM_005094	NΔ	0.000827	
	9	121702606	- C	~	0.110700	p.0300K		NM 001100977	ro2009/E/29	0.000027	
	9	131702090	G	A	C.G443A	p.K146Q	exon/	NIVI_001100877	15200645456	0.000413	
	9	135277447	C	G	C.G762C	p.Q254H	exon2	NM_007344	NA	0.000000	
DPH7	9	140449957	C	1	c.G1093A	p.A365T	exon9	NM_138778	NA	0.000000	
SFMBT2	10	7423832	A	G	c.T29C	p.M10T	exon2	NM_001018039	rs141352828	0.000000	
RBP3	10	48388554	G	A	c.C2324T	p.T775M	exon1	NM_002900	rs201724324	0.000415	
PPA1	10	71977620	G	Т	c.C245A	p.A82E	exon4	NM_021129	NA	0.000000	
TBATA	10	72541674	G	А	c.C160T	p.R54W	exon4	NM_152710	NA	0.000414	
CDH23	10	73538046	G	А	c.G5168A	p.R1723H	exon38	NM 022124	rs189361642	0.000000	
FBXW4	10	103384550	Ğ	Δ	C C788T	p T263M	exon6	NM 022039	NA	0.000000	
KNDC1	10	135020716	с С	Δ	C G3655A	p. 1200W	6Y0n20	NM 1526/2	NΔ	0.000000	
	10	406020710	G	~	0.03033A	p.D1219N	exunzu	NM 001125052		0.000000	
SIGIRR	11	406932	G	L T	C.C/90G	p.Q264E	exone	NW_001135053	NA	0.000434	
RASSE7	11	562229	C	1	C.C2751	p.A92V	exon3	NM_001143993	NA	0.000000	
IMEM80	11	704536	G	A	c.G742A	p.A2481	exon6	NM_001276274	rs140750324	0.000000	
OTOG	11	17593709	Т	С	c.T2074C	p.S692P	exon17	NM_001277269	rs7106548	0.000000	
OTOG	11	17667439	G	С	c.G8726C	p.W2909S	exon55	NM_001277269	rs11024357	0.000000	
LGR4	11	27390603	т	С	c.A1667G	p.N556S	exon18	NM_018490	NA	0.000000	
DCDC1	11	31327261	С	Т	c.G655A	p.D219N	exon6	NM 181807	NA	0.000000	
ELP4	11	31703564	С	т	c.C1373T	p.T458I	exon10	NM 001288726	NA	0.000000	
PAX6	11	31814879	G	Δ	c C1139T	n S380I	exon9	NM_001310159	rs3026384	0 000000	
ACCS	11	44104752	Δ	G	c A1145G	n H382R	exon13	NM_001127219	rs201202479	0.000833	
ACCC AVRDC2	11	47360808	C C	T	c C2125A	p.1100211	000021	NM 000256	NA	0.000000	
	11	47300090	C	- -	C.GZ125A	p.D709N	exonz i		INA NA	0.000000	
	11	55567692	C	1	0.07871	p.P2635	exoni	NIVI_001001952	NA	0.000000	
JR5W2	11	55682040	A	G	c.119C	p.S7P	exon1	NM_001001960	NA	0.000000	-
OR9Q2	11	57958338	G	A	c.G376A	p.V126M	exon1	NM_001005283	NA	0.000413	
BEST1	11	61727452	С	A	c.C776A	p.P259H	exon7	NM_001300786	NA	0.000416	1
ATG2A	11	64669448	С	Т	c.G4105A	p.G1369S	exon29	NM_015104	rs143404952	0.000000	
PCNXL3	11	65403904	С	Т	c.C5636T	p.P1879L	exon34	NM 032223	NA	0.000000	(
SART1	11	65744148	С	т	c.C1768T	p.R590C	exon14	NM_005146	NA	0.000538	
I RP5	11	68207302	Ğ	Ċ	c G2663C	n G888A	exon21	NM 001291902	NA	0.000000	
TDCND	11	699/9973	Č	Ť	c C1505T	p.000001	0x00121	NM 130075	NA	0.000000	
	11	700040073	C	1	0.015951		exuino	NM 001120026	INA ro104146104	0.000000	
LENHBI	11	73362899	G	A	C.G257A	р.каон	exon3	NW_001130036	IS184116184	0.000426	
FAIS	11	92086054	1	G	C.1776G	p.1259R	exon1	INIVI_001008781	NA	0.000000	
KDM4E	11	94758987	A	G	c.A266G	p.K89R	exon1	NM_001161630	NA	0.000000	
PGR	11	100933406	С	Т	c.G1984A	p.V662I	exon4	NM_000926	rs150584881	0.000413	
MMP13	11	102816478	Т	G	c.A1212C	p.R404S	exon9	NM_002427	NA	0.000414	
OR10S1	11	123847636	Α	G	c.T763C	p.C255R	exon1	NM_001004474	NA	0.000000	
OR10G7	11	123908916	С	А	c.G793T	p.D265Y	exon1	NM_001004463	NA	0.000000	
KLRC3	12	10568304	А	G	c.T677C	p.1226T	exon6	NM 002261	NA	0.000000	
TAS2R20	12	11149658	Δ	Ğ	c T817C	n S273P	exon1	NM 176889	rs150448607	0.000413	
PDE34	10	20522242	Ģ	ĉ	c G125C	n G42A	ovon1	NM 000021	N/A	0.000424	
	12	19100040	G		0.01200	p.042A		NM 001009410		0.000424	
	12	40109043		Ğ	0.0109/0	p.53001	exonito	NIVI_UU1098416	INA	0.000000	
ASIC1	12	50468007	G	A	c.G640A	p.G214S	exon1	NIM_001256830	NA	0.000000	
MARS	12	57894189	G	A	c.G1177A	p.A393T	exon10	NM_004990	rs141340466	0.000827	
RHGEF25	12	58010651	G	Т	c.G1717T	p.A573S	exon15	NM_182947	NA	0.000000	
SRGAP1	12	64437300	С	Т	c.C746T	p.A249V	exon6	NM_020762	NA	0.000000	
SRGAP1	12	64536271	G	А	c.G3077A	p.R1026H	exon22	NM 020762	NA	0.000000	
GNS	12	65110525	A	G	c T1655C	n 552P	exon14	NM 002076	NA	0.000000	
BC1D30	12	65237176	G	C C	c G949C	n E3170	evong	NM 015270	NΔ	0 000430	
	12	76760470	^	6	0.03490	p.c.017Q	0100		11/1	0.000400	
	12	10/034/2	A	L T	0.120390		exuing	NIVI_001003712	15199004130	0.000000	
	12	09000042		1	0.033/A	p.D.1.3N	exun4	NIVI_UUT 199777	INA	0.000020	
HKF1BP1L	12	100452762	G	A	c.C2293T	p.R765W	exon14	NM_015054	rs369358032	0.000826	
ACACB	12	109577466	G	Α	c.G256A	p.G86S	exon1	NM_001093	rs371386144	0.000000	
OAS1	12	113346391	С	G	c.C231G	p.D77E	exon2	NM_001032409	NA	0.000000	
MED13L	12	116457747	G	А	c.C656T	p.T219M	exon6	NM_015335	rs191743300	0.000000	
ACADS	12	121176662	С	т	c.C973T	p.R325W	exon8	NM_000017	rs121908006	0.000000	
IRRC63	13	46840996	Δ	Ċ	c A1439C	n Y480S	exonQ	NM 001282460	rs41284167	0.000000	
	10	102515400	~	Ť	C C 1000T	p.14000	01010	NM 000400	NIA	0.000000	
	13	103515408	G		0.019091	p.A6375	exono	INIVI_000123	INA	0.000000	
PARP2	14	20820490	A	G	c.A584G	p. 195C	exon/	NIVI_001042618	15369902077	0.000826	
RNASE11	14	21052549	С	A	c.G85T	p.E29X	exon3	NM_145250	NA	0.000826	
TTC6	14	38091460	G	С	c.G239C	p.R80P	exon3	NM_001310135	NA	0.000000	
TTC6	14	38256794	Т	С	c.T3436C	p.F1146L	exon17	NM_001310135	rs75245849	0.000000	
			0	-	07054	DOOOLI	0.0000	NIM 001200112	********	0.000000	

med Raiv preprin	t doi ₁ <u>https</u>	://5029393/7	0.110 1 /2023	.08,24.23	28.44957¢hi	s versignypo	stechAugu	J\$\$\$\$\$660000000000000000000000000000000	copyright hol	der forothis p	prepring
SA Which was I	not certifie	ed5 py1 pegg	review) is th	ne author/i available	tunder a Co	has granted		v a license to dis	play the prepr	Intdibberbeti	uty. 3
CHURC1,CHURC1-FNTB	14	65381181		avquiable	C.C49T	p.R17C	exon	NM_001202559	NA	0.000414	2
PLEKHH1	14	68038492	G	A	C.G1458A	p.M4861	exon10	NM_020715	NA	0.000833	1
AMN	14	103394845	G	A	c G290A	n G97D	exon4	NM_030943	NA	0.000000	1
PACS2	14	105849743	C	Т	c.C1673T	p.A558V	exon16	NM 001100913	NA	0.000000	3
FMN1	15	33446344	Т	С	c.A772G	p.K258E	exon4	NM_001277313	rs61744870	0.000000	0
EMC4	15	34520042	С	G	c.C350G	p.S117X	exon3	NM_001286420	NA	0.000413	5
CASC5	15	40937249	С	А	c.C5853A	p.N1951K	exon15	NM_144508	NA	0.000000	0
NUSAP1	15	41657631	C T	Т	c.C620T	p.T207l	exon6	NM_001243144	NA	0.000000	1
VPS39	15	42454330	I	C	c.A2360G	p.N/8/S	exon23	NM_015289	NA	0.000413	2
DUOX2	15	43033990	C	Δ	c G979T	p.Co115 p.F327X	exon9	NM 014080	ΝA	0.000000	5
VPS13C	15	62182571	G	A	c.C9005T	p.A3002V	exon65	NM 017684	NA	0.000000	3
TLN2	15	63055808	Ā	C	c.A5008C	p.I1670L	exon37	NM_015059	NA	0.000000	4
IGDCC4	15	65694752	С	Т	c.G637A	p.V213M	exon4	NM_020962	rs143723846	0.000000	6
MAP2K1	15	66782894	С	A	c.C1123A	p.L375I	exon11	NM_002755	NA	0.000413	5
TLE3	15	70349848	C	T	c.G1006A	p.A336T	exon11	NM_001282982	NA	0.000000	5
I HSD4 ND2E2	15	72057393	G	A	C.G1544A	p.K515K	exonitu	NIVI_001286429		0.000413	5
SH2D7	15	78393619	т	G	c T1024G	p.1209A	exon5	NM 001101404	NA	0.000000	0
ADAMTSL3	15	84566637	Ċ	Ť	c.C1495T	p.R499W	exon14	NM 001301110	NA	0.000000	6
PIGQ	16	632973	С	Т	c.C1622T	p.P541L	exon10	NM_148920	NA	0.000425	2
IGFALS	16	1840816	С	Т	c.G1717A	p.G573S	exon2	NM_001146006	NA	0.000000	1
RPL3L	16	1997238	С	G	c.G645C	p.E215D	exon5	NM_005061	NA	0.000000	6
C16orf96	16	4606707	C	A	c.C217A	p.P73T	exon1	NM_001145011	NA	0.000827	0
C160/796	16	4020210	G	A	C.G1735A	p.A5791	exon5	NW 002705	rs140117380	0.000833	0
PPI	16	4934433	C	Ť	c G1010A	n R337H	exon10	NM_002705	rs145641114	0.000417	4
ERCC4	16	14015973	Ă	G	c.A293G	p.Y98C	exon2	NM 005236	NA	0.000000	5
GGA2	16	23479011	С	Т	c.G1742A	p.R581H	exon17	NM_015044	rs185467966	0.000826	7
ATXN2L	16	28843540	С	А	c.C1354A	p.P452T	exon11	NM_001308230	NA	0.000413	4
RABEP2	16	28925790	С	T	c.G661A	p.A221T	exon5	NM_024816	NA	0.000852	6
TIGAL	16	30522254	C	1 -	c.C24201	p.S807L	exon21	NM_001114380	rs376221007	0.000000	0
SRCAP ITEG1	16	30747554	C	T	C.C67631	p.R2255C	exon32	NIVI_000002	NA NA	0.000000	6
ADCY7	16	50327353	G	A	c G776A	p.1104R	exon5	NM 001114	NA	0.000000	3
FAM65A	16	67579353	c	G	c.C3118G	p.L1040V	exon18	NM_001193522	NA	0.000841	0
WWP2	16	69970237	G	Т	c.G682T	p.G228C	exon9	NM_199424	NA	0.000413	6
ZNF821	16	71898823	С	Т	c.G169A	p.E57K	exon3	NM_017530	NA	0.000000	0
GLG1	16	74519713	Т	C	c.A1519G	p.1507V	exon8	NM_001145666	NA	0.000000	4
ATP2C2	16	84493147	I	A	c.12369A	p.V790E	exon24	NM_001286527	NA	0.000000	2
C160/195	16	87730200	C C	A	C.G3561	p.G119V	exon4	NM 020655	INA re200827482	0.000000	1
GEMIN4	17	648141	G	A	c C3142T	p.1/2/10	exon2	NM_015721	NA	0.000000	4
BHLHA9	17	1173958	č	т	c.C101T	p.S34L	exon1	NM_001164405	NA	0.000000	1
METTL16	17	2324092	С	Т	c.G995A	p.R332H	exon9	NM_024086	rs142808274	0.000000	2
OR1G1	17	3030757	G	А	c.C89T	p.S30F	exon1	NM_003555	NA	0.000413	1
CNTROB	17	7838405	A	G	c.A536G	p.N179S	exon4	NM_001037144	NA	0.000417	3
NCOR1	17	16004670	C	1 -	c.G2305A	p.V769I	exon17	NM_001190438	NA	0.000413	0
MYO19	17	34852184	G	Δ	c C2224T	p.K10H	exon23	NM 025109	NA	0.000000	1
KLHL10	17	40003568	Ă	т	c.A1358T	p.Y453F	exon4	NM 152467	NA	0.000414	4
FAM134C	17	40733974	С	Т	c.G1258A	p.G420R	exon9	NM_178126	NA	0.000826	0
WNK4	17	40948576	G	Т	c.G3709T	p.A1237S	exon18	NM_032387	NA	0.000414	3
CDC27	17	45219686	A	С	c.T1104G	p.1368M	exon10	NM_001293091	rs78080061	0.000000	3
CDC27	17	45219688	Т	C	c.A1102G	p.1368V	exon10	NM_001293091	rs200712699	0.000000	4
	17	45219702	T	C	C.A1088G	p.N3635	exon10	NM_001293091	rs199774308	0.000000	4
CDC27	17	45232007	A	C	c T710G	p.112423	exon7	NM 001293091	NA	0.000000	4
CDC27	17	45232109	A	Ğ	c.T703C	p.S235P	exon7	NM_001293091	rs76383230	0.000000	4
MYCBPAP	17	48585968	G	А	c.G62A	p.G21D	exon1	NM_032133	NA	0.000000	2
ABCC3	17	48755543	С	Т	c.C3668T	p.P1223L	exon25	NM_003786	NA	0.000000	8
SOX9	17	70120115	С	A	c.C1117A	p.P373T	exon3	NM_000346	NA	0.000000	1
DNAI2	17	72308160	C	I	c.C14771	p.R493W	exon12	NM_001172810	NA	0.000000	5
GPRUDU CD2001 E	17	72443155	C	A	C.C1350A	p. 1450X	exon4	NIVI_018653		0.000000	0
DNAH17	17	76567792	G	Ĉ	c C612G	p.F131L	exon4	NM 173628	NA	0.000000	0
CEP295NL	17	76887951	c	т	c.G635A	p.R212Q	exon3	NM 001243540	NA	0.000000	0
CCDC40	17	78061568	č	Ť	c.C2612T	p.S871L	exon15	NM_001243342	rs367596393	0.000494	1
CEP131	17	79173297	С	А	c.G1076T	p.R359L	exon10	NM_001009811	NA	0.000000	0
SLC38A10	17	79220401	G	А	c.C2315T	p.T772M	exon16	NM_001037984	rs374394310	0.000000	0
CHST9	18	24497189	A	С	c.T366G	p.S122R	exon6	NM_031422	NA	0.000000	0
RI12	18	40323564		U T	C.A548G	p.K183R	exon5	NM_002930	NA	0.000000	1
SALLS SRND2	10 10	1123586	т	с С	C A404C	p.13661 n E1354	exon2	NM 001100122	NΑ	0.000858	2
GAMT	19	1399827	Ġ	A	c.C292T	p.R98W	exon2	NM 000156	NA	0.000000	2 5
PTPRS	19	5214604	č	Т	c.G3121A	p.V1041I	exon20	NM_130853	rs116515629	0.000827	2
ANGPTL4	19	8436337	G	А	c.G856A	p.V286I	exon5	NM_001039667	rs200918932	0.000000	1
MRPL4	19	10369185	С	G	c.C649G	p.L217V	exon7	NM_015956	NA	0.000000	6
C19orf44	19	16620790	T	C	c.T1630C	p.W544R	exon5	NM_001288834	NA	0.000000	4
FKBP8	19	18652762	G	A	c.C19T	p.P7S	exon2	NM_001308373	NA	0.000000	2

NDOGERASiv pre	eprint doi₁6ttps vas not certifi		0.110 <u>4</u> /202 review) is	23.08 ₆ 24.232 the author/f	2 <mark>94455</mark> 4dhis iunderowho	veraion pos has granted	sted Augu d med Rxiv	ust 25, 292365 he	e copyright hold	der forothis p ntdingerpetu	reprint ity. ₂
FFAR2	19	35941491	Itisma	de av a ilable	under a CC	-BY 4 0. 616	ernätional	1005306	rs143092631	0.000000	0
WDR62	19	36595720	G	Т	c.G4362T	p.E1454D	exon32	NM 001083961	NA	0.000000	2
NEKBIB	19	39397878	Ğ	Ť	c.G379T	p.V127L	exon4	NM 001243116	NA	0.000000	2
SARS2	19	39406709	т	A	c A1315T	p T439S	exon14	NM 017827	rs200202461	0.000416	1
PAK4	19	39664500	Ċ	A	c.C489A	p.D163E	exon3	NM 001014834	NA	0.000000	2
CEACAM5	19	42219668	Ă	G	c A803G	p Q268R	exon4	NM 001291484	NA	0.000413	1
SIX5	19	46269328	C	т	c G1651A	p.V551M	exon3	NM 175875	NA	0.000000	3
CCDC8	19	46915205	Č	Ť	c G863A	p. G288E	exon1	NM_032040	rs201827579	0.000000	0
CRX	10	48342884	Č	Ť	c C560T	n T187	exon4	NM_000554	NA	0.000414	1
HAS1	19	52217119	Č	Ġ	c G1295C	n W432S	exon5	NM 001297436	NA	0.000855	2
ZNE468	10	53348534	Δ	G	c T158C	n 153T	exon4	NM_001277120	rs73069429	0.000000	0
I AIR1	19	54866948	G	Δ	c C739T	n R247W	exonQ	NM_001289023	rs200218727	0.000000	2
RDH13	19	55568152	C	Т	c G209A	n R700	exon3	NM_001145971	NA	0.000000	5
ZNE628	19	55994880	G	Δ	c G2320A	n V774I	exon3	NM 033113	NΔ	0.000426	1
ZNF154	10	58213053	C	т	c G364A	n G122S	exon3	NM_001085384	re202082426	0.000420	1
STK35	20	2082672	G	Δ	c G1/54	n 4/9T	exon1	NM 080836	13202002420 ΝΔ	0.000618	0
	20	26971/1	C C	^	c.C.262T	p.7431		NM 023068	re150358287	0.000010	1
USDA 12B	20	3720025	G	~	c.G2021	p.L00A		NM 001107327	NA	0.000820	3
SIVAID	20	10570290	0	Č Č	0.0304A	p. V 3021	exonE	NM_001000609	ro100062495	0.000000	1
	20	17640746	C	G T	0.03050	p.1102K	exon2	NM 004597	ro200124791	0.000508	2
	20	20200629	G	, C	0.0407A	p.F 130H		NIM_004307	15200124701 NIA	0.000000	3
DULZL I	20	30309020	G	L T	c.C394G	p.K132G	exon2	NIM 021222		0.000000	2
	20	32241319	C	1	C.G603A	p.G200D	exuno	NIM_030884	INA 10000104	0.000630	1
	20	33303103	G	A	C.G2051A	p.E951K	exon26	NIVI_020664	15370690124	0.000535	0
BPI	20	30930930	A	G	C.A430G	p.1144V	exon4	INIM_00101725	15144409725	0.000826	1
SIVX21	20	44462562			C.C41	p.HZY	exon	NIVI_001042632	NA NA	0.000000	3
SULF2	20	46305861	1 T	A	C.A12111	p.K404W	exon9	NM_001161841	NA	0.000000	5
SPATA2	20	48524990	I	C T	C.A38G	p.D13G	exon2	NM_001135773	NA	0.000413	5
NRIP1	21	16338385	C		C.G2129A	p.R/10H	exon4	NM_003489	NA	0.000000	/
PFKL	21	45/25/85	C	1 -	C.C2021	p.P685	exon4	NM_001002021	rs138883373	0.000000	0
	21	45821691	C		C.C24491	p.L817F	exon16	NM_003307	NA	0.000413	5
C210/158	21	47734824	C	1	C.G97A	p.v33M	exon4	NM_001286463	rs/5/98864	0.000000	1
IL1/RA	22	17584415	A	G	c.A794G	p.N265S	exon8	NM_001289905	rs201250724	0.000000	0
CECR2	22	17983890	C	G	C.C223G	p.P75A	exon/	NM_001290046	NA	0.000413	6
SLC25A18	22	18070827	G	A	c.G/12A	p.A2381	exon8	NM_001303484	NA	0.000000	0
CABIN1	22	24561553	A	1	c.A48161	p.11606S	exon30	NM_001201429	NA	0.000000	3
TFIP11	22	26894893	C	G	c.G1378C	p.E460Q	exon10	NM_012143	NA	0.000000	5
RHBDD3	22	29656346	A	G	c.1952C	p.w318R	exono	NM_012265	NA	0.000000	0
SLC5A4	22	32650193	A	G	c.1143C	p.L48P	exon2	NM_014227	NA	0.000000	4
MYH9	22	36688118	G	C	c.C4258G	p.Q1420E	exon31	NM_002473	rs200510675	0.000000	5
IL2RB	22	37524507	G	A	c.C12851	p.L429F	exon10	NM_000878	NA	0.000434	4
SLC16A8	22	38477353	1	C	c.A692G	p.E231G	exon4	NM_013356	NA	0.000480	0
BAIAP2L2	22	38484968	G	A	c.C9051	p.S302L	exon10	NM_025045	NA	0.000430	1
GTSE1	22	46712073	G	A	c.G1196A	p.R399Q	exon7	NM_016426	NA	0.000000	0
CELSR1	22	46931599	T	C	c.A1469G	p.Q490R	exon1	NM_014246	rs200630932	0.000000	0
OFD1	Х	13779315	C	Т	c.C2372T	p.P791L	exon17	NM_003611	NA	0.000826	1
DMD	Х	31697509	Т	С	c.A475G	p.K159E	exon10	NM_004013	NA	0.000000	2
CXorf67	Х	51151176	C	G	c.C1308G	p.N436K	exon1	NM_203407	NA	0.000000	0
WDR44	Х	117532396	C	A	c.C1162A	p.P388T	exon7	NM_001184966	NA	0.000827	0
DCAF12L1	Х	125685729	A	Т	c.T863A	p.L288Q	exon1	NM_178470	NA	0.000000	3
UBL4A	Х	153713967	G	С	c.C385G	p.R129G	exon4	NM_014235	NA	0.000852	3
UBL4A	Х	153713969	С	A	c.G383T	p.S128I	exon4	NM_014235	NA	0.000000	2

^aPhysical position in UCSC Genome Browser in Human Feb. 2009 Human GRCh37/hg19 Assembly.

^bReference allele in UCSC Genome Browser.

^cAllele observed in this study.

^dAllele frequency in Japanese in Human Genetic Variation Database (https://www.hgvd.genome.med.kyoto-u.ac.jp/).

^eNumber of methods for predicting variant as deleterious.

Supplementary Table3. De novo varia	ants in e	each family											me
No. of	i	<u>ء</u> - -	ç	ر		Substitution			Frec	fuency		,	IRxiv
Gene symbol Family predictions ^a	Chr	Position	Refč	Alt	cDNA Amir	no acid Exon	Transcript ID	SNO	Japanese ^e	European ^f (non-Finnish)	Gene description	Gene e	au de de de de de de de de de de de de de
MY018B P5 4	22	26177721	ပ	ს	c.C2232G c.C2	2232G exon10	NM_032608	rs371844616	0.000507	0.000000	Myosin XVIIIB	Skeletal m	isele, heart
BTAF1 P7 4	10	93748956	ပ	ი	c.C2473G p.P	3825A exon20	NM_003972	rs774232595	0.00000.0	0.000000	BTAF1 RNA polymerase II, B-TFIID transcription factor-associated	Lymphocy	, Herve
EED P11 1	11	85981134	G	A	c.G976A p.A	(326T exon10 1	VM_001308007	rs1023860960	0.00000.0	0.000000	Embryonic ectoderm development	Lymphocy	
MUC3A P15 0	2	100550974	A	ს	c.A1555G p.T	-519A exon2	NM_005960	NA	0.000000.0	0.000000	Mucin-3A	Small intes	tine, colon
Abbreviations: NA, not applicable												y pc	oi.or
^a Number of methods for predicting del	leteriou	is variant.											g/10
^b Physical position in UCSC Genome E	Browse	r in Human F	⁻ eb. 20	09 Hur	man GRCh37/hg	119 Assembly.						It is	.110
^c Reference allele in UCSC Genome E	Browse	Ļ										s ma	1/20
^d Allele observed in this study.												ide a	23.(
^e Allele frequency in Japanese in Hum	an Ger	netic Variatior	n Datak	h) asec	1ttps://www.hgvd.	.genome.med.kyc	to-u.ac.jp/).					availa)8.24
^f Allele frequency in European gnomAE	J (https	s://gnomad.bi	roadins	stitute.c	org/).							able	1.232
^g Top two tissues showing highest expr	ression	I level in GTE	Ex (rele	ase V£	8, 54 non-diseas	ed tissue sites acr	oss nearly 1000 i	ndividuals)				unde	2944
												er a C	55; th
												C-B	nis ve
												Y 4.(ersio
) Inte	n pos
												rnatio	ited A
												nal li	ugus

st 25, 2023. The copyright holder for this preprint a license to display the preprint in perpetuity. icense.

family
each
.⊆
variants
site
splice
-able4
5
nentary
e
d

Supplementary	Table4.	Splice	site variants	in eac	:h famil	ly							med
	÷	ō	a : !	ج ۱		-			Freq	uency		vinci	۔ Rxiv ا
Gene symbol	Family	r S	Position	Ket	Alt	Splice region	Substitution	> 20	Japanese ^d	European ^e (non-Finnish)	Gene description	Gene ext	ັດ ເດິດ ຜູ້ ຍອprir
ATG7		3	11468277	G	U	splice acceptor	AG→AC	rs756690200	0.000000	0.000008	Autophagy related 7	Fibroblast, e	t <u>ö</u> tööi
WDR45B	+ +	17	80579677	⊢	U	splice acceptor	AG→CG	NA	0.000000	0.000000	WD repeat domain 45B	Testis, fallop	and tube
HBD	1	11	5255444	U	⊢	splice acceptor	AG→AA	rs35408031	0.000000	0.000026	Hemoglobin, delta	Whole blood	s Spleen
LILRB3	-	19	54721187	c	L	splice donor	GT→AT	rs147121453	0.000000	0.000134	Leukocyte immunoglobulin-like receptor, subfamily B, member 3	Whole blood	spleen
FAM216B	P15	13	43361020	G	F	splice donor	GT→TT	NA	0.000413	0.000000	Family with sequence similarity 216, member B	Heart, fallop	an D ube
Abbreviations: I	IA, not a	applical	ble									It is	1101
	<u> </u>											ma	/20

Physical position in UCSC Genome Browser in Human Feb. 2009 Human GRCh37/hg19 Assembly.

^bReference allele in UCSC Genome Browser.

^cAllele observed in this study.

^dAllele frequency in Japanese in Human Genetic Variation Database (https://www.hgvd.genome.med.kyoto-u.ac.jp/).

^eAllele frequency in European gnomAD (https://gnomad.broadinstitute.org/).

^T Top two tissues showing highest expression level in GTEx (release V8, 54 non-diseased tissue sites across nearly 1000 individuals)

1023.08.24.23294455; this version posted August 25, 2023. The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Index available under a CC-BY 4.0 International license .

family
each
.⊆
variants
deletion
and
Insertion
Table5.
Supplementary

e5. Insertior	srtior	ו and del	etion variants in	each family										(med
	a : :	a		ę				Substitution			Free	luency		whic	- IRxiv
nily Cnr Position	r Position"	sition		Ref	Alť	E XONIC TUNCTION	cDNA	Amino acid	Exon	Transcript ID	Japanese ^d	European ^e (non-Finnish)		Gene 🕸 Gene	dession date
8 2 232458458	232458458	158458			GTACATGT	frameshift insertion	c.796_797insGTACATGT	p.A266fs	exon1	NM_152614	0.000000	0.00000.0	testis expressed 44	Testis, Fed	abian Tube
1 6 43275414	43275414	75414			GT	frameshift insertion	c.263_264insAC	p.T88fs	exon4	NM_206922	0.000416	0.00000.0	cysteine-rich protein 3	Tes <mark>ta</mark> Testa	Brain
4 7 30951718 - 30951719	30951718 - 30951719	- 30951719		AG		frameshift deletion	c.194_195del	p.Q65fs	exon1	NM_198098	0.000000	0.00000.0	aquaporin 1	You	6un
7 8 30703471 - 30703475	30703471 - 30703475	- 30703475		TACTT		frameshift deletion	c.3059_3063del	p.K1020fs	exon1	NM_031271	0.000000	0.00000.0	testis expressed 15	Testi <mark>s</mark>	
8 19 45026932 - 45026938 T	45026932 - 45026938 T	- 45026938 T		CAGGAC		frameshift deletion	c.476_482del	p.G159fs	exon4	NM_001102597	0.000000	0.00000	carcinoembryonic antigen-related cell adhesion molecule 20	Small int <mark>e</mark> d f	01/∰o∵io
														rev I).1 ⁻

Abbreviations: NA, not applicable

^aPhysical position in UCSC Genome Browser in Human Feb. 2009 Human GRCh37/hg19 Assembly.

^bReference allele in UCSC Genome Browser.

^cAllele observed in this study.

^dAllele frequency in Japanese in Human Genetic Variation Database (https://www.hgvd.genome.med.kyoto-u.ac.jp/).

^eAllele frequency in European gnomAD (https://gnomad.broadinstitute.org/).

¹Top two tissues showing highest expression level in GTEx (release V8, 54 non-diseased tissue sites across nearly 1000 individuals)

101/2023.08.24.23294455; this version posted August 25, 2023. The copyright holder for this preprint view) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.